🔗 Share this article

While the US undertakes historic revisions to its vaccination recommendations, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccinations during the pandemic and has focused upon possible deaths after COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Public health authorities had intended to unveil radical revisions to the childhood immunization program earlier this month, bringing the US with the Danish immunization schedule, according to reports – a major change that would place the US out of step with many the global community with little proof for benefit. This reveal has been delayed until the new year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US to become more in line with Denmark, a society with comprehensive healthcare and a population approximately the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Background

Dr. Høeg has little discernible background in drug development, oversight or administrative roles, which has been standard for past heads of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who ran CBER have had.”

The drug center has an immense range of responsibilities at the agency, she pointed out.

“Everybody just focuses on the new drug program, but the generic drug division authorizes thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and more, and each of these need to be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a major administrative aspect to the role, which supervises in excess of 5,000 staff members. “It is a enormous management job, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

When asked about questions about Dr. Høeg's fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “questions stem from inaccurate premises”.

“Her experience matches the functions of her position,” the official said, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious one-day therapy clearance system that allegedly troubled her former heads. “How are these therapies being selected for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of pharmaceuticals, with the exception of vaccines.”

Public Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if concerning, track record, Howard said. She published a analysis using unconfirmed crowd-sourced reports to assess the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the current federal leadership featured altering guidelines for recently developed shots and halting “unnecessary” immunizations, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly suggested preventing teenage boys from receiving COVID-19 vaccinations.

“She is an all-around true believer who begins with her preconceived notions and reverse-engineers to fit the data in a highly deceptive, dishonest manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|